Renaissance Capital logo

Graybug Vision Priced, Nasdaq: GRAY

Phase 2 biotech developing long-acting formulations of drugs for ocular diseases.

Industry: Health Care

Latest Trade: $16.50 0.00 (0.0%)

First Day Return: +3.1%

Return from IPO: +3.1%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. Our novel proprietary technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes. Our lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, a potent inhibitor of neovascular growth and permeability, which are leading causes of retinal disease. We are developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration, or wet AMD, and diabetic macular edema, or DME. In our Phase 1/2a clinical trial, GB-102 administered as a single 1 mg dose was well-tolerated in wet AMD patients and demonstrated durable clinical evidence of disease control of at least six months in approximately 88% of patients in this cohort. GB-102 is currently in a dose-ranging, controlled and masked safety and efficacy Phase 2b clinical trial in patients with wet AMD. We expect to report topline data from this trial in the first half of 2021.
more less
IPO News for Graybug Vision
more
IPO Data
IPO File Date 09/04/2020
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.6
Deal Size ($mm) $90
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 09/24/2020
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 5.6
Deal Size ($mm) $90
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Redwood City, CA
Founded 2015
Employees 24
Website www.graybug.com